51. Bivalirudin for Pediatric Procedural Anticoagulation: A Narrative Review.
- Author
-
Zaleski KL, DiNardo JA, and Nasr VG
- Subjects
- Adolescent, Age Factors, Antithrombins adverse effects, Antithrombins pharmacokinetics, Child, Child, Preschool, Drug Administration Schedule, Drug Dosage Calculations, Hemorrhage chemically induced, Hirudins adverse effects, Hirudins pharmacokinetics, Humans, Infant, Infant, Newborn, Models, Biological, Peptide Fragments adverse effects, Peptide Fragments pharmacokinetics, Perioperative Care adverse effects, Recombinant Proteins administration & dosage, Recombinant Proteins adverse effects, Recombinant Proteins pharmacokinetics, Risk Assessment, Risk Factors, Thrombosis blood, Thrombosis diagnosis, Thrombosis etiology, Treatment Outcome, Antithrombins administration & dosage, Blood Coagulation drug effects, Cardiac Catheterization adverse effects, Cardiac Surgical Procedures adverse effects, Cardiopulmonary Bypass adverse effects, Hirudins administration & dosage, Peptide Fragments administration & dosage, Perioperative Care methods, Thrombosis prevention & control
- Abstract
Bivalirudin (Angiomax; The Medicines Company, Parsippany, NJ), a direct thrombin inhibitor, has found increasing utilization as a heparin alternative in the pediatric population, most commonly for the treatment of thrombosis secondary to heparin-induced thrombocytopenia. Due to the relative rarity of heparin-induced thrombocytopenia as well as the lack of Food and Drug Administration-approved indications in this age group, much of what is known regarding the pharmacokinetics and pharmacodynamics of bivalirudin in this population has been extrapolated from adult data. This narrative review will present recommendations regarding the use of bivalirudin for procedural anticoagulation in the pediatric population based on the published literature.
- Published
- 2019
- Full Text
- View/download PDF